Hyaluronate la ogolaaday oo loo isticmaalo xayeysiinta xawilaadda
Supartz, oo ah xalka soodhiyam-salalka, waa mid ka mid ah shuban-biyoodka loo isticmaalo fayadhowrka. Supartz waxa si toos ah loogu duraa jilibka si uu u soo celiyo boogaha iyo miirista walxaha dheecaanka synovial (ie, dareeraha wadajirka ah). Sodium hyaluronate oo loo isticmaalo Supartz ayaa laga soo saaraa shanlada digaaga. Sodium hyaluronate waa polysaccharide kaas oo ka kooban dib-u-celinta unugcharide ee glucuronic acid iyo N-acetylglucosamine .
Ogolaanshaha Supartz iyo Supartz Fx
Suptarz waxaa la ansaxiyay FDA bishii Janaayo 24, 2001 si loogu daaweeyo jilibka osteoarthritis ee bukaanada kuwaas oo ku fashilmay in ay helaan gargaar ku filan oo daaweyn daaweyn ah, oo ay ka mid yihiin jimicsi, daweyn jireed, daawo xanuun , gargaar dhaqaale, iyo xirmo kulul ama qabow . Isticmaalka xubno kale ayaa la baarayaa. Supartz waxa loo isticmaali jiray Japan tan iyo 1987. Waxaa la isku duraa hal mar toddobaadkii muddo 5 toddobaad ah. Qaar ka mid ah bukaannada ayaa laga yaabaa inay helaan jawaab wanaagsan ka dib 3 toddobaad.
Oktoobar 12, 2015, Bioventus, oo ka shaqeeya Supartz, ayaa ku dhawaaqay in bilawga Supartz Fx (10 mg sodium hyaluronate lagu kala diro 1.0% nafaqo dabiiciga ah), oo leh calaamad ballaaran oo laga helay Supartz asal ah, oo u oggolaanaya inuu ku celiyo wareegyada cirbadeynta. Inkasta oo calaamadda amniga la ballaariyey si loogu celiyo wareegyada cirbadeynta, waxtarka wareegga celinta looma dhicin.
Digniinta iyo Taxaddarrada
Supartz waa in aan lagu maamulin bukaan kasta oo leh cillad la yaqaan oo loo yaqaan 'sodium hyaluronate'.
Digniinta waa in la isticmaalaa marka la daaweynayo bukaanka xasaasiyadda la og yahay ee borotiinka, ukunta, ama boogaha. Bukaanka qaba infakshan ama maqaarka maqaarka ah ee meesha cirbadda la siinayo waa inaan lagu daaweynin Supartz.
Ammaanka iyo waxqabadka Supartz laguma dhex samayn dumarka uurka leh, ama dumarka nuujinaya.
Isticmaalkeeda laguma baran carruurta.
Saameynada Caadiga ah
Waxyeellooyinka caamka ah ama dhacdooyinka xun ee la xidhiidha Supartz waxaa ka mid ah:
- Xanuun wadajir ah oo aan lahayn caabuq
- Xanuunka dhabarka
- Xanuun aan gaar aheyn
- Diidmada goobta daaweynta
- Madax xanuun
Barar ama xanuunka, oo ah mid ku-meel-gaadh ah, wuxuu ku dhici karaa wadajir ah oo lagu duray Supartz. Bukaan-socodka waxaa lagula talinayaa inay ka fogaadaan waxqabadyada culus ama miisaan culus 48 saacadood kadib duritaanka.
Khadadka hoose
Falanqaynta 5 tijaabo oo si fiican loo qorsheeyey ayaa muujiyay farqi weyn oo u dhexeeya Supartz iyo kooxaha xakameynaya marka la eego dhacdooyinka khalkhalka. Inkasta oo ammaanka Supartz iyo daraasadihii kale ee la sameeyey ay kobcinayeen daraasaadka kiliinikada, waxtarka ayaa laga dooday. Marka laga hadlayo waxtarka, Dib-u-eegista Cochrane ayaa soo gabagabeysay in faahfaahinta viskosuppling ay ka waxtar badan tahay placebo, laakiin waxaa jiray daraasado kale oo hoos u dhacay isagoo caddeeyay in cirbadaha ay bixiyaan xanuun badan oo xanuun.
Ilaha:
Supartz Fx. Macluumaadka Qorista. Bioventus. http://www.supartzfx.com/wp-content/uploads/2015/07/SUPARTZ_FX_Package_Insert.pdf
Bioventus oo bilawday Supartz Fx hadda iyadoo la adeegsanayo calaamadda amniga ee lagu soo celinayo wareegtooyinka loo yaqaan 'Osteoarthritis'. Oktoobar 12, 2015.
http://www.bioventusglobal.com/news/press-releases/bioventus-launches-supartz-fx%E2%84%A2-now- wax-u-dhicitaan -label-repeat-injection-cycles
Hyaluronic acid (Supartz): dib u eegis lagu sameeyo isticmaalka osteoarthritis ee jilibka. Xildhibaanka Baarlamaanka. Daroogooyinka & Aging. Nofeembar 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20964466